通过向首席执行官发放4 000万股股份,以及用于临床前研究的收益,Gentral Biosciences筹集了340 000英镑。 Genflow Biosciences raised £340,000 by issuing 40 million shares to its CEO, with proceeds funding preclinical research.

基因流生物科学公司于2025年10月2日宣布,通过在招股说明书豁免下向首席执行官埃里克·莱尔发行每股0.85便士的4000万股新股,筹集了34万英. Genflow Biosciences announced on October 2, 2025, it raised £340,000 by issuing 40 million new shares at 0.85 pence each to CEO Eric Leire under a prospectus exemption. 这些股份立即被转售给第三方购买者,第三方购买者收到24个月的许可证,每股1.2便士。 The shares were immediately resold to a third-party purchaser, who received 24-month warrants at 1.2 pence per share. 新的股份定于10月9日进入伦敦证券交易所的主要市场,将该公司发行的股份增加到493 547 942。 The new shares are set for admission to the London Stock Exchange’s main market on October 9, increasing the company’s issued share count to 493,547,942. 收益将资助正在进行的临床前研究,包括一项关于其铅疗法(GF-1002)的狗研究,并计划进行新陈代谢性机能障碍相关steatohepatitis试验。 Proceeds will fund ongoing preclinical research, including a dog study on its lead therapy GF-1002 and planned trials for metabolic dysfunction-associated steatohepatitis.